New­ly-pub­lic Im­muno­vant an­nounces first proof-of-con­cept suc­cess

Im­muno­vant an­nounced its first batch of proof-of-con­cept da­ta for its an­ti­body against a rare au­toim­mune dis­ease, a month af­ter its biggest ri­val slid one of its dogs out of the race.

In a tiny study of thy­roid eye dis­ease, 4 out of 7 pa­tients giv­en IMVT-1401 saw their clin­i­cal ac­tiv­i­ty score im­prove by 2 or more points and 3 out of 7 saw their prop­to­sis — eye pro­tru­sion — im­prove. There was a 65% re­duc­tion in IgG, the pro­tein IMVT-1401 is meant to block, which was “near­ly iden­ti­cal to mod­eled pre­dic­tions for dos­ing reg­i­men” in the tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.